AllianceBernstein
AVXL icon

AllianceBernstein’s Anavex Life Sciences AVXL Stock Holding History

AllianceBernstein’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Buy
146,300
+31,100
+27% +$92K ﹤0.01% 2788
2026
Q1 		$410K Hold
115,200
– – ﹤0.01% 2739
2025
Q4 		$410K Hold
115,200
– – ﹤0.01% 2759
2025
Q3 		$1.03M Hold
115,200
– – ﹤0.01% 2345
2025
Q2 		$1.06M Hold
115,200
– – ﹤0.01% 2252
2025
Q1 		$988K Hold
115,200
– – ﹤0.01% 2252
2024
Q4 		$1.24M Buy
115,200
+7,360
+7% +$56.6K ﹤0.01% 2217
2024
Q3 		$613K Sell
107,840
-13,040
-11% -$75.2K ﹤0.01% 2564
2024
Q2 		$510K Buy
120,880
+40,480
+50% +$164K ﹤0.01% 2658
2024
Q1 		$409K Sell
80,400
-7,640
-9% -$43K ﹤0.01% 2673
2023
Q4 		$820K Buy
88,040
+5,000
+6% +$34.4K ﹤0.01% 2374
2023
Q3 		$544K Sell
83,040
-6,560
-7% -$52.2K ﹤0.01% 2532
2023
Q2 		$728K Hold
89,600
– – ﹤0.01% 2451
2023
Q1 		$768K Hold
89,600
– – ﹤0.01% 2353
2022
Q4 		$830K Hold
89,600
– – ﹤0.01% 2374
2022
Q3 		$925K Hold
89,600
– – ﹤0.01% 2330
2022
Q2 		$897K Hold
89,600
– – ﹤0.01% 2409
2022
Q1 		$1.1M Buy
89,600
+200
+0.2% +$2.46K ﹤0.01% 2396
2021
Q4 		$1.55M Hold
89,400
– – ﹤0.01% 2275
2021
Q3 		$1.6M Hold
89,400
– – ﹤0.01% 2282
2021
Q2 		$2.04M Buy
89,400
+71,000
+386% +$1.05M ﹤0.01% 2179
2021
Q1 		$275K Sell
18,400
-38,200
-67% -$417K ﹤0.01% 2939
2020
Q4 		$306K Hold
56,600
– – ﹤0.01% 2842
2020
Q3 		$258K Hold
56,600
– – ﹤0.01% 2871
2020
Q2 		$278K Buy
56,600
+27,700
+96% +$105K ﹤0.01% 2912
2020
Q1 		$91K Buy
+28,900
New +$101K ﹤0.01% 2976
2018
Q2 		– Sell
-29,700
Closed -$82K – 3109
2018
Q1 		$82K Hold
29,700
– – ﹤0.01% 2969
2017
Q4 		$96K Hold
29,700
– – ﹤0.01% 2967
2017
Q3 		$123K Hold
29,700
– – ﹤0.01% 3022
2017
Q2 		$158K Buy
+29,700
New +$172K ﹤0.01% 3044

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein's AVXL Position: Q2 2026 in Review

AllianceBernstein increased its Anavex Life Sciences (AVXL) stake by 27% in Q2 2026, buying an estimated $92K and bringing the position to 146,300 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

AllianceBernstein first reported a position in AVXL in Q2 2017 and has held it in 30 quarters since. The position peaked at $2.04M in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • AllianceBernstein held 146,300 shares of Anavex Life Sciences worth $449K as of Q2 2026.
  • AllianceBernstein bought 31,100 Anavex Life Sciences shares in Q2 2026, an estimated $92K.
  • Anavex Life Sciences made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2788 holding.
  • AllianceBernstein first reported a position in Anavex Life Sciences in Q2 2017 and has held it in 30 quarters since.
  • AllianceBernstein's Anavex Life Sciences position peaked at $2.04M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.